ArticleBiochemical genetics2022
CirRNA circFAM126A Exerts Oncogenic Functions in NSCLC to Upregulate IRS2.
Article in Biochemical genetics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 2 citations in OpenAlex.
- [Progress in the Study of Mechanisms Clinically Relevant to Insulin Resistance and Lung Cancer].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2024Review
- Circular RNA in Non-small Cell Lung Carcinoma: Identification of Targets and New Treatment Modalities.Cancer genomics & proteomics · 2023Review
- Circular RNAs Involved in the Regulation of the Age-Related Pathways.International journal of molecular sciences · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Non-small cell lung cancer (NSCLC) is a common histological subtype of lung cancer, which occupies 80-85% of the proportion in all lung cancer cases. Therefore, this study was designed to clarify the role and underlying molecular mechanisms of circFAM126A in NSCLC. The real-time quantitative polymerase chain reaction (RT-qPCR) assay was conducted to assess circFAM126A, FAM126A, miR-613, and IRS2 expression in NSCLC tissues and cells. The proliferation ability of cells was measured by MTT, EdU, and colony-forming assays. The flow cytometry assay was performed to evaluate cell cycle distribution and apoptosis of NSCLC cells. The migration and invasion were determined by wound healing and transwell matrigel assays, respectively. The interaction relationship between miR-613 and circFAM126A or IRS2 was analyzed by dual-luciferase reporter and RNA pull-down assays. Tumorigenesis in nude mice was conducted to clarify the functional roles of circFAM126A inhibition in vivo. CircFAM126A was obviously overexpressed in NSCLC tissues and cells when compared with controls. The loss-of-functional experiments suggested that knockdown of circFAM126A suppressed proliferation, migration and invasion, as well as caused apoptosis and cell cycle arrest in NSCLC cells, which was abolished by silencing of miR-613. In addition, IRS2 was a target gene of miR-613. Overexpression of miR-613 exerted carcinoma inhibitor role in NSCLC by inhibition of IRS2 expression. Consistently, the silencing of circFAM126A also functioned anti-tumorigenic roles in nude mice in vivo. Mechanistically, circFAM126A could function as a miRNA sponge for miR-613 to regulate the expression of IRS2, thereby regulating proliferation, migration, invasion, apoptosis, and cell cycle arrest in NSCLC cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.